SELUX DIAGNOSTICS, INC.
CHARLESTOWN, MA · Founded 2014 · CIK 0001736293 · Medtech · Private
Rapid phenotypic antibiotic susceptibility test (AST) system using next-generation phenotyping platform for fastidious bacteria and yeast
- Grants
- $2.3M
- 4 awards
- Sector median: 1
- Raised
- $124M
- 6 Form D · Feb 2024
- 32 months since last filing
- Contracts
- $63M
- 1 award · Health and Human S
- #13 of 4531 in medtech
- Patents
- 40
- 19 granted · 21 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20152017201920212023
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Novel Platform for Improving Access to and Efficacy of Fertility Treatments | $216,546 | |
| Federal grant | Department of Health and Human Services · Phase I · FAST platform for same-shift, complete antibiotic menu antibiotic susceptibility testing | $298,851 | |
| Private capital raised | Form D · SEC | $23,500,001 | |
| Federal contract | Department of Health and Human Services · Igf::ot::igf | $62,626,467 | |
| Federal grant | Department of Health and Human Services · Phase II · Next-generation phenotypic antimicrobial susceptibility test platform: rapid results and comprehensive menus | $760,449 | |
| Private capital raised | Form D · SEC | $8,999,997 | |
| Federal grant | Department of Health and Human Services · Phase II · Next-generation phenotypic antimicrobial susceptibility test platform: rapid results and comprehensive menus | $1,000,000 | |
| Private capital raised | Form D · SEC | $813,907 | |
| Private capital raised | Form D · SEC | $2,500,000 | |
| Private capital raised | Form D · SEC | $48,175,947 | |
| Private capital raised | Form D · SEC | $40,000,000 |
Federal grant · SBIR/STTRFederal contract · USAspendingForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 10 | Crossject SA | $104M | $10M |
| 11 | Stratatech Corporation | $98M | $3.0M |
| 12 | RAPISCAN LABORATORIES, INC. | $68M | — |
| 13 | SELUX DIAGNOSTICS, INC. | $63M | $124M |
| 14 | BANYAN BIOMARKERS, INC. | $62M | $14M |
| 15 | FIREFLY NEUROSCIENCE, INC. | $56M | $19M |
| 16 | RIVANNA MEDICAL, INC. | $52M | $370K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Vacic AlexanderExecutive Officer
- James CassidyDirector
- Parker CassidyDirector
- Ingo ChakravartyDirector
- Jamie CondieDirector
- Orhan GazelleDirector
- Michele HealyExecutive Officer
- Steven LufkinDirector · Executive Officer
- Jack PercoskieExecutive Officer
- Michael RubinDirector
- Erich SchellerDirector
- Adam SteelExecutive Officer
- Eric SternDirector · Executive Officer · Promoter
- Aleksandar VacicExecutive Officer · Promoter
- John WilsonExecutive Officer
- Scott YapheDirector
- Stephen ZacharyDirector
Patents
- Systems And Methods For Performing Antimicrobial Susceptibility Testinggranted
- System, Method And Interface For Parallel Processing Of Antimicrobial Susceptibility Tests Using Different Samplesapplication
- Methods For Improved Rapid Antimicrobial Susceptibility Testinggranted
- System, Method And Interface For Parallel Processing Of Antimicrobial Susceptibility Tests Using Different Samplesgranted
- Performing Antimicrobial Susceptibility Testing And Related Systems And Methodsapplication
- System, Method And Interface For Parallel Processing Of Antimicrobial Susceptibility Tests Using Different Samplesgranted
- Systems And Methods For Performing Antimicrobial Susceptibility Testinggranted
- Assays For Improving Automated Antimicrobial Susceptibility Testing Accuracygranted
- Performing Antimicrobial Susceptibility Testing And Related Systems And Methodsgranted
- Devices, Systems, And Methods For Sample Tube Processingapplication
- Assays And Reagents For Antimicrobial Susceptibility Testinggranted
- Antimicrobial Cartridges And Processes For Multiplexed Antimicrobial Susceptibility Testinggranted
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.